STK10 and cancer: Simultaneous inhibition of several proviral kinases by a single drug (i.e., “polypharmacology”), in this case the 3 catalytically active ErbBs and possibly STK10, RAF1, and RIPK2, may further increase the effectiveness while minimizing viral resistance, as previously shown in cancer (51).